Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA.
Idaho National Laboratory, Idaho Falls, ID, USA.
Physiol Rep. 2021 Jan;9(1):e14701. doi: 10.14814/phy2.14701.
The Corona Virus Infectious Disease-19 (COVID-19) pandemic has played havoc on both the global health and economy. It is necessary to find a molecular signature that differentiates between low-risk and high-risk individuals. Pathogens, including viruses of the upper respiratory tract, utilize mucin proteins to enter into host cells. Mucins are critical components of innate immunity and also play important roles in infectious disease progression. Their expression is regulated by different cytokines during infection and inflammation. A comparison of mucin signatures between an asymptomatic versus symptomatic and between patients with mild versus severe symptoms could help identify other important proteins involved in the pathology of this new virus. Recent studies on the pathogenicity of the SARS-CoV-2 have found receptors that help its entry into the cells. In this review, we present an overview of how mucins are connected to the pathogenicity of the virus and propose that studying the glycome and mucin signature may lead to the development of a biomarker in predicting the susceptibility, progression, and response to therapy in COVID-19 patients.
新型冠状病毒肺炎（COVID-19）大流行对全球健康和经济造成了严重破坏。有必要找到一种分子特征，将低风险和高风险个体区分开来。病原体，包括上呼吸道病毒，利用粘蛋白蛋白进入宿主细胞。粘蛋白是先天免疫的关键组成部分，在传染病的进展中也发挥着重要作用。它们的表达在感染和炎症过程中受到不同细胞因子的调节。无症状与有症状患者之间以及轻症与重症患者之间的粘蛋白特征比较，有助于确定该新型病毒发病机制中的其他重要蛋白。最近对 SARS-CoV-2 致病性的研究发现了有助于其进入细胞的受体。在这篇综述中，我们概述了粘蛋白与病毒致病性的关系，并提出研究聚糖和粘蛋白特征可能有助于开发预测 COVID-19 患者易感性、进展和治疗反应的生物标志物。
